clinical cases DDIs

Date of report 13 May 2019

Reported case interaction between **Rilpivirine** and **Omeprazol**

Drugs suspected to be involved in the DDI

Victim
Rilpivirine

Daily Dose
25 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
Dec. 19, 2016

End date
Ongoing

Perpetrator
Omeprazol

Daily Dose
20 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
Unknown

End date
Ongoing

Complete list of drugs taken by the patient

Antiretroviral treatment

Dolutegravir
Lamivudine
Rilpivirine

Complete list of all comedications taken by the patient, included that involved in the DDI

Omeprazol, desloratadine, ipratropium bromide, escitalopram, furosemide, folic acid, lorazepam, magnesium, calcium, paracetamol, quetiapine, salbutamol, trimetroprim, sulphametoxazol, terbutaline, trazodone.

Clinical case description

Gender

Female

Age

54

eGFR (mL/min)

Hemodialysis

Liver function impairment

No

Description

Despite potential interacion between rilpivirine and omeprazol, viral load continued being undetectable. Treatment with rilpivirine plus omeprazol (20 mg qd) was maintained.

Clinical Outcome

No unwanted outcome

Editorial Comment

Rilpivirine should not be co-administered with omeprazole as significant decreases in rilpivirine plasma concentrations may occur (due to gastric pH increase), which may result in loss of therapeutic effect of rilpivirine.

University of Liverpool Recommendation

- These drugs should not be coadministered

For more information click here